Israel’s TheraCoat Said to Seek More Than $20 Million Before IPO
This article is for subscribers only.
TheraCoat, a developer of treatments for urinary tract diseases, is seeking to raise more than $20 million in coming months as it prepares for an initial public offering in New York, people with knowledge of the matter said.
The Israeli company, which says its gel technology allows cancer drugs to stick better to the bladder wall, may be listed on the Nasdaq Stock Market as early as this year, one of the people said, declining to be named as the matter is confidential. The company will seek a valuation of about $200 million in the IPO, the people said.